Literature DB >> 26683525

The clinical challenges of akathisia.

James B Lohr1, Carolyn A Eidt1, Areej Abdulrazzaq Alfaraj1, Mounir A Soliman1.   

Abstract

Akathisia is one of the most vexing problems in neuropsychiatry. Although it is one of the most common side effects of antipsychotic medications, it is often difficult to describe by patients, and is difficult to diagnose and treat by practitioners. Akathisia is usually grouped with extrapyramidal movement disorders (ie, movement disorders that originate outside the pyramidal or corticospinal tracts and generally involve the basal ganglia). Yet, it can present as a purely subjective clinical complaint, without overt movement abnormalities. It has been subtyped into acute, subacute, chronic, tardive, withdrawal-related, and "pseudo" forms, although the distinction between many of these is unclear. It is therefore not surprising that akathisia is generally either underdiagnosed or misdiagnosed, which is a serious problem because it can lead to such adverse outcomes as poor adherence to medications, exacerbation of psychiatric symptoms, and, in some cases, aggression, violence, and suicide. In this article, we will attempt to address some of the confusion surrounding the condition, its relationship to other disorders, and differential diagnosis, as well as treatment alternatives.

Entities:  

Keywords:  Parkinson; akathisia; antipsychotic; movement disorder; review

Mesh:

Year:  2015        PMID: 26683525     DOI: 10.1017/S1092852915000838

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  11 in total

1.  Review of cariprazine in management of psychiatric illness.

Authors:  Rebecca H Campbell; Michael Diduch; Kristen N Gardner; Christopher Thomas
Journal:  Ment Health Clin       Date:  2018-03-23

2.  Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.

Authors:  Koen Demyttenaere; Johan Detraux; Giorgio Racagni; Kristof Vansteelandt
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

Review 3.  Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM!

Authors:  Srinagesh Mannekote Thippaiah; Rachel E Fargason; Badari Birur
Journal:  Psychopharmacol Bull       Date:  2021-06-01

Review 4.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 5.  Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview.

Authors:  Maurizio Pompili; Ross J Baldessarini; Alberto Forte; Denise Erbuto; Gianluca Serafini; Andrea Fiorillo; Mario Amore; Paolo Girardi
Journal:  Int J Mol Sci       Date:  2016-10-11       Impact factor: 5.923

Review 6.  Tardive Akathisia with Asymmetric and Upper-body Presentation: Report of Two Cases and Literature Review.

Authors:  Gholamali Shahidi; Mohammad Rohani; Renato Puppi Munhoz; Fahimeh H Akhoundi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-05-29

7.  Risperidone-Induced Tardive Akathisia: A Rare Antipsychotic Side Effect with Management Issues.

Authors:  Biswa Ranjan Mishra; Rajeev Ranjan; Debadatta Mohapatra; Santanu Nath
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

8.  Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies.

Authors:  Ágota Barabássy; Barbara Sebe; Károly Acsai; István Laszlovszky; Balázs Szatmári; Willie R Earley; György Németh
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-07       Impact factor: 2.570

9.  Olanzapine-Induced Parkinsonism and Akathisia: A Case Report.

Authors:  Varun Jaitpal; Sushil Gawande
Journal:  Cureus       Date:  2022-01-18

10.  A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.

Authors:  Peter J Weiden; Raymond Manning; Curt D Wolfgang; J Michael Ryan; Linda Mancione; Guangyang Han; Saeed Ahmed; Mallery G Mayo
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.